In the evolving pharmaceutical landscape of 2026, companies face unprecedented financial pressures on multiple fronts, including rising costs and shrinking opportunities for revenue generation. The Inflation Reduction Act (IRA), now in its fourth year, continues to compress peak sales windows for top-selling drugs through price negotiations. At the same time,…
Clinical research networks continue to play a pivotal role in supporting pipeline development. However, the importance of these networks extends well beyond the conduct of clinical trials. Clinical investigators can support market conditioning, serve as important levers for informing evidence-based clinical pathways/guidelines, and aid in the generation of real-world evidence…
Economic and clinical value has become the basis for both differentiation and maintaining premium pricing, and the importance of the economic and clinical value case is likely only to increase. This trend is truly global in scope, applies to multiple key stakeholder groups (payers, physicians, and patients), and is particularly…
Increasingly, pharmaceutical companies are being asked – if not required – to demonstrate that their products deliver economic and clinical value to a wide range of stakeholders, including payers, providers, pharmacy benefit managers (PBMs), and patients. In the past, regulatory approval alone was sufficient to successfully bring a new product…
There are several important reasons for stakeholders to be optimistic about prospects for biosimilars. During the past few years, questions about the underlying technology and market acceptance have begun to resolve themselves in a positive manner. Regulatory pathways are being defined, and major players and investments are lining up. Most…
The healthcare system — in the U.S. and globally — is responding to the need to reduce costs and improve outcomes. The foremost implication for manufacturers of pharmaceuticals, devices, and diagnostics is a drive to demonstrate the economic and clinical value of their products to all stakeholders… including patients. This…
